Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Summary Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF). Ruxolitinib was assessed in JUMP, a large (N = 2233), phase 3b, expanded‐access study in MF in countries without access to ruxolitinib outside a clinical trial, which included patien...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2020-06, Vol.189 (5), p.888-903
Hauptverfasser:	Al‐Ali, Haifa Kathrin, Griesshammer, Martin, Foltz, Lynda, Palumbo, Giuseppe A., Martino, Bruno, Palandri, Francesca, Liberati, Anna Marina, Coutre, Philipp, García‐Hernández, Carmen, Zaritskey, Andrey, Tavares, Renato, Gupta, Vikas, Raanani, Pia, Giraldo, Pilar, Hänel, Mathias, Damiani, Daniela, Sacha, Tomasz, Bouard, Catherine, Paley, Carole, Tiwari, Ranjan, Mannelli, Francesco, Vannucchi, Alessandro M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Anemia Anemia - chemically induced Enzyme inhibitors Female Hematology Humans Janus kinase Janus Kinase 1 - antagonists & inhibitors Janus kinase 2 Janus Kinase 2 - antagonists & inhibitors Kaplan-Meier Estimate Leukemia, Myeloid, Acute - etiology Male Middle Aged Myelofibrosis Neoplasms - etiology Patients Platelet Count Platelets Primary Myelofibrosis - blood Primary Myelofibrosis - complications Primary Myelofibrosis - drug therapy Progression-Free Survival Proportional Hazards Models Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use ruxolitinib Safety Spleen Spleen - pathology Splenomegaly Splenomegaly - etiology symptoms Thrombocytopenia Thrombocytopenia - chemically induced Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF). Ruxolitinib was assessed in JUMP, a large (N = 2233), phase 3b, expanded‐access study in MF in countries without access to ruxolitinib outside a clinical trial, which included patients with low platelet counts (
ISSN:	0007-1048 1365-2141
DOI:	10.1111/bjh.16462